Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Servier Completes the Acquisition of Symphogen
Details : As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : Sym021
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Servier Canada
Deal Size : Undisclosed
Deal Type : Acquisition
Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline
Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 03, 2020
Lead Product(s) : Sym021
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Servier Canada
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
